Novo Nordisk A/S, a healthcare company, is engaged in the discovery, development, manufacturing, and marketing of pharmaceutical products and services. The company markets its products in approximately 180 countries. Segments The company operates through two business segments, Diabetes Care and Biopharmaceuticals. Diabetes Care This segment covers insulins, GLP-1, other protein-related products (such as glucagon, protein-related delivery systems, and needles), obesity, and oral antidiabetic drugs. Biopharmaceuticals This segment covers the therapy areas of haemophilia care, growth hormone therapy, hormone replacement therapy and inflammation. Markets and Distribution The company’s insulin and other pharmaceutical products are marketed and distributed through subsidiaries, distributors, and independent agents with responsibility for specific geographical areas. The primary markets are North America, China, Japan, and the major European countries. Its international operations are in Algeria, Argentina, Australia, Brazil, India, Russia, and Turkey. Patents The company’s major delivery devices are protected by various patents of which the first would expire in January 2019. In the U.S. NovoLog/NovoRapid is patent protected until December 2014. In addition to the drug compound patent, the company holds a formulation patent on NovoLog/NovoRapid, which provides coverage until 2017 in all major markets. NovoLog Mix/NovoMix is protected by patents in Japan, Europe, and the United States. In Japan the drug compound patent expires in June 2014, in the United States the drug compound patent expires in December 2014 and in Europe the drug compound patent expires on a country-by-country basis throughout 2014 and 2015. In addition, the company holds a formulation patent on NovoLog Mix/NovoMix in the United States, which provides coverage until June 2017. Significant Events In September 2014, Novo Nordisk has signed a partnership deal with the Egyptian Company for Production of Vaccines (EGYVAC). The two companies plan to collaborate on the construction of a human insulin factory in Egypt, with Novo Nordisk transferring technology related to the manufacture of insulin. In addition to the partnership, Novo Nordisk plans to establish 26 specialist diabetes treatment centres and provide 60,000 patients with free insulin pens. History Novo Nordisk A/S was founded in 1925.
novo-nordisk a/s-spons adr
Phone: 45 44 44 88 88
Fax: 45 44 49 05 55www.novonordisk.com
|AbbVie Inc||$57.23 USD||-0.53|
|Amgen Inc||$138.82 USD||-1.64|
|Biogen Idec Inc||$323.50 USD||-7.31|
|Bristol-Myers Squibb Co||$50.53 USD||-0.65|
|Reckitt Benckiser Group PLC||5,275 GBp||-30.00|
|View Industry Companies|
Sponsored Financial Commentaries
To contact NOVO-NORDISK A/S-SPONS ADR, please visit www.novonordisk.com. Company data is provided by Capital IQ. Please use this form to report any data issues.